The size of the Asia-Pacific RNAi Drug Delivery Market has been estimated at USD 9.66 billion in 2021. It is projected to reach USD 34.52 billion by 2026, at a CAGR of 29% during the forecast period.
The APAC market for RNAi drug delivery is expected to be driven by the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and other genetic disorders. In addition, a rising number of academic research and activities are stimulating the use of novel drug delivery methods and drug enhancements by boosting stability. Furthermore, other factors such as increasing awareness about the RNAi therapies and their benefits, growing disposable income, and favorable reimbursement policies are propelling the market growth.
Due to the numerous benefits offered by RNA interference technology in medicine and therapeutics, the therapeutics segment is expected to accelerate. Moreover, the government authorities in developing countries are taking steps to provide improved medication delivery to all segments of the population to improve health care services, fueling the RNAi drug delivery market's growth.
On the other hand, the growing geriatric population, the prevalence of infectious diseases, and a significant increase in the demand for RNAi drug delivery technologies in emerging countries such as China, India, and Japan are expanding the APAC Regional market growth. Furthermore, the medical research companies are constantly working to produce RNA treatments, and key market players are adopting key market strategies to gain a competitive advantage. The strategies include Partnerships, mergers, and acquisitions.
However, the high cost of RNAi therapy development is expected to be impeding the market growth. In addition, other factors such as an increased risk of failure, lack of skilled specialists in drug control laboratories, and a lack of proper distribution networks of RNAi medication delivery due to the weak healthcare infrastructure in developing countries are constraining the market development.
This research report on the Asia-Pacific RNAi Drug Delivery market has been segmented and sub-segmented into the following categories.
By Drug Delivery:
By Therapeutic Application:
By Country:
The APAC is one of the fasting growing regions globally in the RNAi drug delivery market. The regional market growth is attributed to the growing healthcare infrastructure, significant investments, and favorable reimbursement policies. The Asia Pacific region accounted for the most significant proportion of the worldwide RNAi medication market in 2020. Emerging countries such as China, India, and Japan significantly contribute to the APAC regional market growth. RNAi technology allows for a focused approach to cancer treatment, which is ideal for receiving precise treatment. The rise in chronic diseases such as cancer and carter dysfunction has resulted in a steady increase in demand for RNAi drugs across the region. Scientists are currently working to identify the genes that cause cancer and develop an RNAi drug to combat them. For a few years, this approach has been quickly growing.
China accounted for the largest share of the RNAi market over the forecast period and is most likely to witness a predominant share in the coming years. The presence of well-established healthcare infrastructure, technological advancements, and prevalence of chronic diseases contribute to the country's market growth.
KEY MARKET PLAYERS:
Alnylam Pharmaceuticals Inc., Merck & Co. Inc, Dicerna Pharmaceuticals Inc., Tekmira Pharmaceuticals Corp., Access Pharmaceuticals Inc., Sirnaomics Inc., Isis Pharmaceuticals Inc, RXi Pharmaceuticals Corp., Calondo Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Silence Therapeutics plc, Traversa Therapeutics Inc., Marina Biotech Inc., Tacere Therapeutics Inc., and PhaseRx Inc. are some of the key companies in the APAC RNAi drug delivery market.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug delivery
5.1.1 Introduction
5.1.2 nanoparticle drug delivery technology
5.1.3 pulmonary drug delivery technology
5.1.4 nucleic acid drug delivery technology
5.1.5 aptamer drug delivery technology
5.1.6 Y-o-Y Growth Analysis, By Drug Delivery
5.1.7 Market Attractiveness Analysis, By Drug delivery
5.1.8 Market Share Analysis, By drug Delivery
5.2 Therapeutic Application
5.2.1 Introduction
5.2.2 infectious diseases
5.2.3 cardiology
5.2.4 oncology
5.2.5 neurology
5.2.6 ophthalmology
5.2.7 metabolic disorders
5.2.8 Y-o-Y Growth Analysis, By Therapeutic Application
5.2.9 Market Attractiveness Analysis, By Therapeutic Application
5.2.10 Market Share Analysis, By Therapeutic Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Delivery
6.1.3.3 By Therapeutic Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Delivery
6.1.4.3 By Therapeutic Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Delivery
6.1.5.3 By Therapeutic Application
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Alnylam Pharmaceuticals Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Merck & Co. Inc
8.3 Access Pharmaceuticals Inc.
8.4 Dicerna Pharmaceuticals Inc.
8.5 Tekmira Pharmaceuticals Corp.
8.6 Isis Pharmaceuticals Inc
8.7 Calondo Pharmaceuticals Inc.
8.8 Marina Biotech Inc.
8.9 RXi Pharmaceuticals Corp
8.10 Quark Pharmaceuticals Inc
8.11 Silence Therapeutics plc
8.12 Traversa Therapeutics Inc.
8.13 Tacere Therapeutics Inc
8.14 Sirnaomics Inc.
8.15 PhaseRx Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
